Drug-induced eruptive melanocytic nevi

References

• Rogers T, Marino ML, Raciti P, et al. Biologically distinct subsets of naevi: a review. G Ital Dermatol Venereol. 2016;151:365–384.
   PubMed Web of Science ®Google Scholar
• Roh MR, Eliades P, Gupta S, et al. Genetics of melanocytic nevi. Pigment Cell Melanoma Res. 2015;28:661–672.
   PubMed Web of Science ®Google Scholar
• Ross AL, Sanchez MI, Grichnik JM. Molecular nevogenesis. Dermatol Res Pract. 2011;2011:463184.
   PubMedGoogle Scholar
• Kato S, Lippman SM, Flaherty KT, et al. The conundrum of genetic “drivers” in benign conditions. J Natl Cancer Inst. 2016;108:djw036.
   Google Scholar
• Navarini AA, Kolm I, Calvo X, et al. Trauma as triggering factor for development of melanocytic nevi. Dermatology. 2010;220:291–296.
   PubMed Web of Science ®Google Scholar
• Kvaskoff M, Bijon A, Mesrine S, et al. Association between melanocytic nevi and risk of breast diseases: the French E3N prospective cohort. PLoS Med. 2014;11:e1001660.
   PubMed Web of Science ®Google Scholar
• Chan MP, Chan MM, Tahan SR. Melanocytic nevi in pregnancy: histologic features and Ki-67 proliferation index. J Cutan Pathol. 2010;37:843–851.
   PubMed Web of Science ®Google Scholar
• Jullien D, Prévot G, Wolkenstein P, et al. Extension en coulee d’un naevus apres syndrome de Lyell. Ann Dermatol Venereol. 1995;122:540–542.
   PubMed Web of Science ®Google Scholar
• Shoji T, Cockerell CJ, Koff AB, et al. Eruptive melanocytic nevi after Stevens-Johnson syndrome. J Am Acad Dermatol. 1997;37:337–339.
   PubMed Web of Science ®Google Scholar
• Lanschuetzer CM, Laimer M, Nischler E, et al. Epidermolysis bullosa nevi. Dermatol Clin. 2010;28:179–183.
   PubMed Web of Science ®Google Scholar
• Firooz A, Komeili A, Dowlati Y. Eruptive melanocytic nevi and cherry angiomas secondary to exposure to sulfur mustard gas. J Am Acad Dermatol. 1999;40:646–647.
   PubMed Web of Science ®Google Scholar
• Hendricks WM. Eruptive blue nevi. J Am Acad Dermatol. 1981;4:50–53.
   PubMed Web of Science ®Google Scholar
• Onsun N, Saraçoğlu S, Demirkesen C, et al. Eruptive widespread Spitz nevi: can pregnancy be a stimulating factor? J Am Acad Dermatol. 1999;40:866–867.
   PubMed Web of Science ®Google Scholar
• Colson F, Arrese JE, Nikkels AF. Localized eruptive blue nevi after herpes zoster. Case Rep Dermatol. 2016;2:446178.
   Google Scholar
• Surinach C, Bahadoran P, Vabres P, et al. Flexural agminated eruptive nevi in Langerhans cell histiocytosis. JAMA Dermatol. 2013;149:635–637.
   PubMed Web of Science ®Google Scholar
• Donati P, Paolino G, Donati M, et al. Cutaneous mastocytosis combined with eruptive melanocytic nevi and melanoma. Coincidence or a linkage in the pathogenesis? J Dermatol Case Rep. 2014;8:70–74.
   PubMedGoogle Scholar
• Krause MH, Bonnekoh B, Weisshaar E, et al. Coincidence of multiple, disseminated, tardive-eruptive blue nevi with cutis marmorata teleangiectatica congenita. Dermatology. 2000;200:134–138.
   PubMed Web of Science ®Google Scholar
• Richert S, Bloom EJ, Flynn K, et al. Widespread eruptive dermal and atypical melanocytic nevi in association with chronic myelocytic leukemia: case report and review of the literature. J Am Acad Dermatol. 1996;35:326–329.
   PubMed Web of Science ®Google Scholar
• McCourt C, Feighery C, McIntyre G, et al. Eruptive nevi in prostate cancer: is this a paraneoplastic phenomenon? Int J Dermatol. 2013;52:212–213.
   PubMed Web of Science ®Google Scholar
• Duvic M, Lowe L, Rapini RP, et al. Eruptive dysplastic nevi associated with human immunodeficiency virus infection. Arch Dermatol. 1989;125:397–401.
   PubMed Web of Science ®Google Scholar
• Betlloch I, Amador C, Chiner E, et al. Eruptive melanocytic nevi in human immunodeficiency virus infection. Int J Dermatol. 1991;30:303.
   PubMed Web of Science ®Google Scholar
• Koelemij I, Massolt ET, van Doorn R. Eruptive melanocytic naevi as a sign of primary adrenocortical insufficiency. Clin Exp Dermatol. 2013;38:927–929.
   PubMed Web of Science ®Google Scholar
• Sünkel S, Wichmann-Hesse A, Gärtner R, et al. Pigmentvermehrung bei Schmidt-Syndrom (polyglandulares Autoimmunsyndrom typ II). Hautarzt. 2001;52:974–976.
   PubMed Web of Science ®Google Scholar
• Zattra E, Fortina AB, Bordignon M, et al. Immunosuppression and melanocyte proliferation. Melanoma Res. 2009;19:63–68.
   PubMed Web of Science ®Google Scholar
• Egberts F, Kaehler KC, Brasch J, et al. Multiple skin metastases of malignant melanoma with unusual clinical and histopathologic features in an immunosuppressed patient. J Am Acad Dermatol. 2008;58:880–884.
   PubMed Web of Science ®Google Scholar
• Szepietowski J, Wasik F, Szepietowski T, et al. Excess benign melanocytic naevi in renal transplant recipients. Dermatology. 1997;194:17–19.
   PubMed Web of Science ®Google Scholar
• Smith CH, McGregor JM, Barker JN, et al. Excess melanocytic nevi in children with renal allografts. J Am Acad Dermatol. 1993;28:51–55.
   PubMed Web of Science ®Google Scholar
• Koseoglu G, Akay BN, Kucuksahin O, et al. Dermoscopic changes in melanocytic nevi in patients receiving immunosuppressive and biologic treatments: results of a prospective case-control study. J Am Acad Dermatol. 2015;73:623–629.
   PubMed Web of Science ®Google Scholar
• Doğan N, Bilen N, Aktürk AŞ, et al. The effects of biological agents on melanocytic nevi: a preliminary report. Turk J Dermatol. 2016;10:14–18.
   Web of Science ®Google Scholar
• Di Cesare A, Riitano A, Suppa M, et al. Frequency of melanocytic nevi in psoriatic patients is related to treatment and not to disease severity. J Am Acad Dermatol. 2013;69:947–953.
   PubMed Web of Science ®Google Scholar
• Alaibac M, Piaserico S, Rossi CR, et al. Eruptive melanocytic nevi in patients with renal allografts: report of 10 cases with dermoscopic findings. J Am Acad Dermatol. 2003;49:1020–1022.
   PubMed Web of Science ®Google Scholar
• Barker JN, MacDonald DM. Eruptive dysplastic naevi following renal transplantation. Clin Exp Dermatol. 1988;13:123–125.
   PubMed Web of Science ®Google Scholar
• Belloni Fortina A, Piaserico S, Zattra E, et al. Dermoscopic features of eruptive melanocytic naevi in an adult patient receiving immunosuppressive therapy for Crohn’s disease. Melanoma Res. 2005;15:223–224.
   PubMed Web of Science ®Google Scholar
• Piaserico S, Alaibac M, Fortina AB, et al. Clinical and dermatoscopic fading of post-transplant eruptive melanocytic nevi after suspension of immunosuppressive therapy. J Am Acad Dermatol. 2006;54:338–340.
   PubMed Web of Science ®Google Scholar
• Woodhouse J, Maytin EV. Eruptive nevi of the palms and soles. J Am Acad Dermatol. 2005;52(5 Suppl 1):S96–S100.
   PubMed Web of Science ®Google Scholar
• Binder B, Ahlgrimm-Siess V, Hofmann-Wellenhof R. Eruptive melanocytic nevi of the palms and soles in a patient with Crohn disease. J Dtsch Dermatol Ges. 2006;4:486–488.
   PubMedGoogle Scholar
• Bovenschen HJ, Tjioe M, Vermaat H, et al. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br J Dermatol. 2006;154:880–884.
   PubMed Web of Science ®Google Scholar
• de Boer NK, Kuyvenhoven JP. Eruptive benign melanocytic naevi during immunosuppressive therapy in a Crohn’s disease patient. Inflamm Bowel Dis. 2011;17:E26.
   PubMed Web of Science ®Google Scholar
• Wonders J, De Boer NK, Van Weyenberg SJ. Spot diagnosis: eruptive melanocytic naevi during azathioprine therapy in Crohn’s disease. J Crohns Colitis. 2012;6:636.
   PubMed Web of Science ®Google Scholar
• Kakrida M, Orengo I, Markus R. Sudden onset of multiple nevi after administration of 6-mercaptopurine in an adult with Crohn’s disease: a case report. Int J Dermatol. 2005;44:334–336.
   PubMed Web of Science ®Google Scholar
• Sekulic A, Colgan MB, Davis MD, et al. Activating BRAF mutations in eruptive melanocytic naevi. Br J Dermatol. 2010;163:1095–1098.
   PubMed Web of Science ®Google Scholar
• John JK, Smalley KS. Identification of BRAF mutations in eruptive melanocytic nevi: new insights into melanomagenesis? Expert Rev Anticancer Ther. 2011;11:711–714.
   PubMed Web of Science ®Google Scholar
• Braun SA, Helbig D, Frank J, et al. Eruptive melanozytare navi unter behandlung einer Myasthenia gravis mit Azathioprin. Hautarzt. 2012;63:756–759.
   PubMed Web of Science ®Google Scholar
• Katsanos KH, Christodoulou DK, Zioga A, et al. Cutaneous nevi pigmentosus during infliximab therapy in a patient with Crohn’s disease: fallacy or coincidence? Inflamm Bowel Dis. 2003;9:279.
   PubMed Web of Science ®Google Scholar
• López V, Molina I, Martín JM, et al. Eruptive nevi in a patient receiving cyclosporine A for psoriasis treatment. Arch Dermatol. 2010;146:802–804.
   PubMedGoogle Scholar
• Lycke J. Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. Ther Adv Neurol Disord. 2015;8:274–293.
   PubMed Web of Science ®Google Scholar
• Marousi S, Karkanis I, Kalamatas T, et al. Immune cells after prolonged natalizumab therapy: implications for effectiveness and safety. Acta Neurol Scand. 2013;128:e1–e5.
   PubMed Web of Science ®Google Scholar
• Zattra E, Fortina AB, Alaibac M. Excess of melanocytic nevi in a patient treated with natalizumab for multiple sclerosis. Eur J Dermatol. 2012;22:416–417.
   PubMed Web of Science ®Google Scholar
• Castela E, Lebrun-Frenay C, Laffon M, et al. Evolution of nevi during treatment with natalizumab: a prospective follow-up of patients treated with natalizumab for multiple sclerosis. Arch Dermatol. 2011;147:72–76.
   PubMedGoogle Scholar
• Pharaon M, Tichet M, Lebrun-Frénay C, et al. Risk for nevus transformation and melanoma proliferation and invasion during natalizumab treatment: four years of dermoscopic follow-up with immunohistological studies and proliferation and invasion assays. JAMA Dermatol. 2014;150:901–903.
   PubMed Web of Science ®Google Scholar
• Planas R, Martin R, Sospedra M. Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life. Patient Relat Outcome Meas. 2014;5:25–33.
   PubMedGoogle Scholar
• Vavricka BM, Baumberger P, Russmann S, et al. Diagnosis of melanoma under concomitant natalizumab therapy. Mult Scler. 2011;17:255–256.
   PubMed Web of Science ®Google Scholar
• Hung WC, Chen SH, Paul CD, et al. Distinct signaling mechanisms regulate migration in unconfined versus confined spaces. J Cell Biol. 2013;202:807–824.
   PubMed Web of Science ®Google Scholar
• Happle R, Koopman RJ. Akrale Navi nach Chemotherapie. Hautarzt. 1990;41:331–332.
   PubMed Web of Science ®Google Scholar
• Martín Hernández JM, Donat Colomer J, Monteagudo Castro C, et al. Nevos acrales eruptivos tras quimioterapia en ninos afectados de leucemia linfoblastica aguda. An Pediatr (Barc). 2006;65:260–262.
   PubMedGoogle Scholar
• Reutter JC, Long EM, Morrell DS, et al. Eruptive post-chemotherapy in situ melanomas and dysplastic nevi. Pediatr Dermatol. 2007;24:135–137.
   PubMed Web of Science ®Google Scholar
• Dertlioglu SB, Bitiren M, Cicek D. A case with postchemotherapy eruptive compound nevus. Indian J Dermatol. 2011;56:737–739.
   PubMedGoogle Scholar
• Arnold SJ, Bowling J. Eruptive acral naevi following chemotherapy for acute lymphoblastic leukaemia follow typical acral dermoscopic patterns. Australas J Dermatol. 2013;54:126–128.
   PubMed Web of Science ®Google Scholar
• Mazaud C, Chevallier B, Sigal ML, et al. Syndrome du naevus eruptif de l’enfant a propos d’un cas. Arch Pediatr. 2015;22:409–413.
   PubMed Web of Science ®Google Scholar
• Bogenrieder T, Weitzel C, Schölmerich J, et al. Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma? Dermatology. 2002;205:174–175.
   PubMed Web of Science ®Google Scholar
• Salopek TG, Mahmood MN. Eruptive melanocytic nevi induced by interferon for nodal metastatic melanoma: case report and review of the literature. J Cutan Med Surg. 2013;17:410–413.
   PubMed Web of Science ®Google Scholar
• Santiago F, Gonçalo M, Reis JP, et al. Adverse cutaneous reactions to epidermal growth factor receptor inhibitors: a study of 14 patients. An Bras Dermatol. 2011;86:483–490.
   PubMed Web of Science ®Google Scholar
• Arnault JP, Mateus C, Escudier B, et al. Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res. 2012;18:263–272.
   PubMed Web of Science ®Google Scholar
• Bennani-Lahlou M, Mateus C, Escudier B, et al. Naevus eruptifs sous sorafenib. Ann Dermatol Venereol. 2008;135:672–674.
   PubMed Web of Science ®Google Scholar
• Kong HH, Sibaud V, Chanco Turner ML, et al. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol. 2008;144:820–822.
   PubMed Web of Science ®Google Scholar
• Uhlenhake EE, Watson AC, Aronson P. Sorafenib induced eruptive melanocytic lesions. Dermatol Online J. 2013;19:18184.
   PubMedGoogle Scholar
• Gupta M, Gupta H, Gupta A. Sorafenib induced acral pigmentation: a new entity. Avicenna J Med. 2015;5:46–48.
   PubMedGoogle Scholar
• Jiménez-Gallo D, Albarrán-Planelles C, Linares-Barrios M, et al. Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib. JAMA Dermatol. 2013;149:624–626.
   PubMed Web of Science ®Google Scholar
• Sibaud V, Munsch C, Lamant L. Eruptive nevi and hair depigmentation related to regorafenib. Eur J Dermatol. 2015;25:85–86.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kang JH, Cho BK, et al. Dysplastic nevus with eruptive melanocytic lesions that developed during nilotinib therapy for chronic myeloid leukemia. Ann Dermatol. 2015;27:782–784.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Kim TM, Kim YJ, et al. Phase II trial of nilotinib in patients with metastatic malignant melanoma harboring KIT gene aberration: a multicenter trial of Korean cancer study group (UN10-06). Oncologist. 2015;20:1312–1319.
   PubMed Web of Science ®Google Scholar
• Gençler B, Gönül M. Cutaneous side effects of BRAF inhibitors in advanced melanoma: review of the literature. Dermatol Res Pract. 2016;2016:5361569.
   PubMed Web of Science ®Google Scholar
• Holderfield M, Nagel TE, Stuart DD. Mechanism and consequences of RAF kinase activation by small-molecule inhibitors. Br J Cancer. 2014;111:640–645.
   PubMed Web of Science ®Google Scholar
• Chu EY, Wanat KA, Miller CJ, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol. 2012;67:1265–1272.
   PubMed Web of Science ®Google Scholar
• Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012;30:2375–2383.
   PubMed Web of Science ®Google Scholar
• Mudaliar K, Tetzlaff MT, Duvic M, et al. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. Hum Pathol. 2016;50:79–89.
   PubMed Web of Science ®Google Scholar
• Schmitt L, Schumann T, Inhoff O, et al. Eruptive nevi mimicking wart-like lesions under selective BRAF inhibition in a 37-year-old female melanoma patient. Case Rep Dermatol. 2013;5:69–72.
   PubMedGoogle Scholar
• Cox AD, Der CJ. The RAF inhibitor paradox revisited. Cancer Cell. 2012;21:147–149.
   PubMed Web of Science ®Google Scholar
• Livingstone E, Zimmer L, Vaubel J, et al. BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management. Chin Clin Oncol. 2014;3:29.
   PubMedGoogle Scholar
• Perier-Muzet M, Thomas L, Poulalhon N, et al. Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy. J Invest Dermatol. 2014;134:1351–1358.
   PubMed Web of Science ®Google Scholar
• Haenssle HA, Kraus SL, Brehmer F, et al. Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy. Arch Dermatol. 2012;148:1183–1185.
   PubMed Web of Science ®Google Scholar
• Boussemart L, Routier E, Mateus C, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24:1691–1697.
   PubMed Web of Science ®Google Scholar
• Chen FW, Tseng D, Reddy S, et al. Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy. JAMA Dermatol. 2014;150:1209–1212.
   PubMed Web of Science ®Google Scholar
• Anforth RM, Carlos GR, Scolyer RA, et al. Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma. Melanoma Res. 2015;25:91–94.
   PubMed Web of Science ®Google Scholar
• Kadekaro AL, Kanto H, Kavanagh R, et al. Significance of the melanocortin 1 receptor in regulating human melanocyte pigmentation, proliferation, and survival. Ann N Y Acad Sci. 2003;994:359–365.
   PubMed Web of Science ®Google Scholar
• Cousen P, Colver G, Helbling I. Eruptive melanocytic naevi following melanotan injection. Br J Dermatol. 2009;161:707–708.
   PubMed Web of Science ®Google Scholar
• Sivyer GW. Changes of melanocytic lesions induced by melanotan injections and sun bed use in a teenage patient with FAMMM syndrome. Dermatol Pract Concept. 2012;2:203a10.
   PubMedGoogle Scholar
• Reid C, Fitzgerald T, Fabre A, et al. Atypical melanocytic naevi following melanotan injection. Ir Med J. 2013;106:148–149.
   PubMedGoogle Scholar
• Schulze F, Erdmann H, Hardkop LH, et al. Eruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II. Eur J Dermatol. 2014;24:107–109.
   PubMed Web of Science ®Google Scholar
• Paurobally D, Jason F, Dezfoulian B, et al. Melanotan-associated melanoma. Br J Dermatol. 2011;164:1403–1405.
   PubMed Web of Science ®Google Scholar
• Ong S, Bowling J. Melanotan-associated melanoma in situ. Australas J Dermatol. 2012;53:301–302.
   PubMed Web of Science ®Google Scholar
• Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology. 2014;228:34–36.
   PubMed Web of Science ®Google Scholar
• Michel JL. Naevus eruptifs sous octreotide. Ann Dermatol Venereol. 2011;138:677–680.
   PubMed Web of Science ®Google Scholar
• Kim DH, Lee JS, Koo DW, et al. Eruptive melanocytic nevi with satellite lesions following insulin treatment in a girl with type 1 diabetes mellitus. J Dermatol. 2015;42:547–548.
   PubMed Web of Science ®Google Scholar
• Tofahrn J, Hundeiker M. Naevus-Eruption nach Thyreoidin mit Spontaninvolution. Z Hautkr. 1976;51:617–620.
   PubMedGoogle Scholar
• Wyatt D. Melanocytic nevi in children treated with growth hormone. Pediatrics. 1999;104:1045–1050.
   PubMed Web of Science ®Google Scholar
• Gkalpakiotis S, Arenberger P, Arenbergerova M. Eruptive multiple Spitz nevi in a patient with epilepsy and drug addiction. J Dtsch Dermatol Ges. 2012;10:267–269.
   PubMed Web of Science ®Google Scholar